Start-up Funding | |
Start-up Expenses to Fund | $258,500 |
Start-up Assets to Fund | $384,000 |
Total Funding Required | $642,500 |
Assets | |
Non-cash Assets from Start-up | $355,000 |
Cash Requirements from Start-up | $29,000 |
Additional Cash Raised | $0 |
Cash Balance on Starting Date | $29,000 |
Total Assets | $384,000 |
Liabilities and Capital | |
Liabilities | |
Current Borrowing | $0 |
Long-term Liabilities | $0 |
Accounts Payable (Outstanding Bills) | $0 |
Other Current Liabilities (interest-free) | $0 |
Total Liabilities | $0 |
Capital | |
Planned Investment | |
Investor 1 | $110,000 |
Investor 2 | $110,000 |
Investor 3 | $110,000 |
Investor 4 | $93,750 |
Investor 5 | $93,750 |
Investor 6 | $62,500 |
Investor 7 | $62,500 |
Other | $0 |
Additional Investment Requirement | $0 |
Total Planned Investment | $642,500 |
Loss at Start-up (Start-up Expenses) | ($258,500) |
Total Capital | $384,000 |
Total Capital and Liabilities | $384,000 |
Total Funding | $642,500 |
Headquarters are located in an office of approximately 4,000 square feet at Chemin d’Etraz 2, CH-1027 Lonay, Switzerland.
The present office space is small. As we add employees, we will have to take on additional space. We expect space to be available in our present building. The office space will have assembly space on site and be equipped to handle shipping.
Bioring SA addresses the surgical repair techniques which are implemented in open heart surgery. This business is based on a patented product owned by the company, which is the Kalangos Biodegradable Ring cardiac implant.
The Bioring biodegradable valvular heart ring (Kalangos mitral or tricuspid ring) has been developed and designed to diminish or reinforce the valvular orifices of the heart. The ring allows a normal growth of the valve in newborn and babies, avoiding stenosis and multiple surgical procedures.
The ring is dimensioned to the size and natural geometry of the valve, and it is manufactured with a specially designed biodegradable polymer called polydioxanone. Once implanted, through the regular absorption of the ring inside the endomyocardiac tissue by simple hydrolysis, the body creates (by reaction) a scar along the ring, characterized by fibrotic tissue presenting an improved resistance to elongation. Once the ring has been completely biodegraded, the rigidity of the fibrotic tissue of the scar is maintaining the valvular orifice at the desired dimension.
As the residual scar is made of the proper biologic tissues of the patient, there is no predisposition to infection, and furthermore, the scar is able to grow normally during the growth process of the newborn.
The Kalangos mitral ring is available in 11 dimensions, covering all phases of development and all adult sizes. The Kalangos tricuspid ring is also available in 11 dimensions. Sizers have been designed to help the surgeon surgeon to choose the right ring dimension.
As of June 2001, Bioring SA has 44 products to sell:
There are already existing heart rings on the market: Duran, Carpentier, Puig-Masada, Cosgrove, but none of them produce a biodegradable ring. The major benefits of Kalangos rings when compared to existing products available on the market are:
And moreover, the ring is attached to a suture-needle system which makes the surgical procedure easier and faster.
Bioring advertisements and sales literature are under development.
Bioring is registered on the Web page of the Chambre Vaudoise du Commerce et de l’Industrie. The company intends to have its own presenting page on the Web once the products have been CE marked.
Bioring SA manufactures its own products, using its in-house development process. The raw materials are provided by a major chemical supplier, which delivers to Bioring SA a customized polymer.
An injection molding press has been specially designed and installed to inject the polymer into the proprietary molds.
All operations, including the packaging of the final product, are done in a controlled environment: class 100 clean room.
The list of suppliers is considered as proprietary information, which is not disclosed here.
Bioring Kalangos biodegradable rings have been internationally protected by patent. A Swiss patent application has been filed in 1997, followed by a worldwide PCT application filed in 2000. Copies are available.
A trademark application is in progress.
The development of the biodegradable polymer may meet other very promising applications in the fields of cardiac and vascular surgery. We are presently in the process of writing the extension of the initial patent and testing the very first prototypes of new implants. No information can be given at this stage.
The market for annuloplasty rings is worth an estimated $250 million at end-user value in 2001, and is projected to grow at 3% per year according to professional forecasts published in specialized issues in 2000. Sources included The European Heart Institute and The National Center for Health Statistics in the USA.
Market leaders are Edwards Laboratories, Sulzer Medica, Medtronic. However, the industry is highly concentrated. The 10 major companies account for 95% of the total market.
The rings for annuloplasty belong to the heart valve repair industry.
We prefer a segmentation by addressed patients. This incorporates some of the product type differences, but in a more practical sense:
Market Analysis | |||||||
Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |||
Potential Customers | Growth | CAGR | |||||
New-born and infant market | 0% | 2,000 | 6,000 | 10,000 | 14,000 | 18,000 | 73.21% |
Adult market | 0% | 2,000 | 10,000 | 14,000 | 20,000 | 22,000 | 82.12% |
Other | 0% | 0 | 0 | 0 | 0 | 0 | 0.00% |
Total | 77.83% | 4,000 | 16,000 | 24,000 | 34,000 | 40,000 | 77.83% |
The following sections outline Bioring SA’s target market segment strategy.
We understand that our target market needs more than just standard rings covered with a polyester mesh. The need grew out of the special needs of neonate cardiac surgery. Our target customer wants to have this new possibility which they consider as a major improvement. There is a need for a high-quality prostheses which solves patient and surgeon problems. We don’t just sell a ring, we sell a new concept and a new surgical procedure.
Our market has finally grown towards more sophisticated technics of valve repair, where the surgeon will try to repair a portion a faulty valve. In the past years, he would have replaced the total valve. Fine repair of cardiac valve is the new trend.
According to The European Heart Institute, (Cardiovascular Device Update, August 98, page 2) the number of congenital heart defects treated in Europe in 1995 represented 24,400 procedures, which represent a rate of 48 surgical procedures per million. In 2002, it is projected to perform 28,000 surgical procedures (50 procedures per million). This market is growing at a annual rate of 1.9%.
According to the same source, the heart valve surgery market has accounted 66,700 procedures in 1995 (131 procedures per million). In 2002, it is projected to amount 84,000 procedures (150 per million), which represent an annual growth rate of 3%.
A recent article published in Cardiovascular Device Update, (December 2000), shows that the European and the U.S. market are practically the same size. The same issue of this paper indicated that the present potential U.S. market for cardiac abnormalities repair amounted $215 million per year, and that the congenital heart defects repair amounted for $149 million per year.
The major players in this industry are international companies. It is a concentrated industry in which there are a few major players.
We are mentioning: Baxter Corporation (U.S.), Boston Scientific (U.S.), Cryolife (U.S.), Edwards Corporation (U.S.), Guidant (U.S.), Medtronic (U.S.), St Jude Medical (U.S.), Sulzer Medica (Switzerland).
Distribution channels are of two types:
The cost of marketing a new class III device is becoming a serious barrier to enter a market. For bioring type of company, the best choice is to deal through national dealers in Europe and a major company in USA.
In the high-end specialty market, particularly in our niche, features are very important. Our target customer is not making selections based on price. The high-tech, innovative aspect, the easy-to-implant aspect, the reduced time of procedure, the anatomical shape, the physiological process and the clinical results are more important than pricing.
In the field of cardiac surgery prostheses, the general trend is to develop anatomical and physiological mimetic implants. The ergonomy of the implant is also important.
In the field of pediatric surgery, as previously mentioned, there is no real competitor. Therefore the strategy of the company is to enter the market together with a well-known market leader, to avoid to be considered as a weak company by the market leaders.
In the field of adult surgery, the company will benefit of the presence on the market of the chosen distributors for pediatric surgery. In this field, our main competitors are: Edwards Laboratories, Sulzer Medica, Medtronic.
Our strategy is based on serving niche markets well. What begins as a customized product, tailored to the needs of a local pediatric cardiac surgeon, can eventually become a niche product that will fit the needs of the pediatric cardiac surgeons worldwide. Our marketing infrastructure is built to reach our customers across broad geographic lines. Our products are designed to fit the need of the international cardiac pediatric surgeons community, as the market presence requires to fulfill with regulatory rules which are quite costly.
Our marketing strategy is based on:
We intend to participate in May 2001 in the 3rd World Congress of Pediatric Cardiology and Cardiac Surgery in Toronto, Canada, where we are showing our product for the first time to the world community.
In September, we intend to participate to the joint meeting of the European Association of Cardio Throracic Surgeons and the European Society for Thoracic Surgery where our consulting surgeon, Dr. Kalangos, is publishing clinical data.
For discriminating pediatric cardiac surgeons who want to benefit from the latest advances with polymer technology, Bioring offers superb anatomical design combined with state-of-the-art technology. For surgeons addressing cardiac adult surgery, unlike other non-biodegradable rings covered with polyester mesh. The Kalangos biodegradable ring, made of polydioxanone, offers an excellent resistance to infection. Polyester mesh is known to be an excellent support for bacterial growth.
In the high-tech products market, pricing is based on the level of other similar products, already on the market. The European end-user market price for a standard cardiac ring is around $1,250. We intend to introduce Kalangos biodegradable ring at the same level of price. Price to distributor is $625, which provides the distributor enough margin to take care of its national market.
The long-range goal is to create enough visibility to achieve the best penetration possible on the different markets.
We are intending to do it through:
Our most important marketing program is CE mark approval. Philippe Le Goff is in charge of it, assisted by Raymond Andrieu and A. Kalangos. This program should be completed for the 1st of June 2001. This program will allow us to sell our ring in Europe. Achievement should be measured by receiving a CE number, which has to be printed on all packaging of the products.
Another key marketing program is the European distribution network. Raymond Andrieu is in charge of it, and most of European distributors should be appointed for July 2001. Achievement should be measured by signed agreements in the different countries.
The next important milestone is the FDA approval process. Raymond Andrieu will be in charge of it, with a budget of $ 200,000 and a milestone date of the 1st of December 2002. Achievement should be measured by receiving the official FDA approval document. This process is intended to be done in close collaboration with the U.S. company in charge of distributing the product in USA.
The sales strategy has been forecasted as follows:
Sales in Europe
In each European country a distributor has been chosen. By signing a distribution agreement, he has to order a minimum quantity of products to be sold in his country. This quantity is to be reviewed each year. He will at first develop the pediatric market, then the adult market. Each distributor is supposed to have a team of salesmen or saleswomen who are in charge of visiting cardiac surgeons in the country. Each salesperson is in charge of several hospitals in one area of the country. In a country like Germany, the distributor should have five or six salesmen or women to cover the country. The distributor should have enough products on the shelves to serve the needs of the country. The salespeople would sell products to public and private hospitals and clinics where cardiac surgery, either pediatric or adult, is performed. Large countries like Germany or France should have around 400 rings permanently on the shelves of the distributor. Invoicing to hospital, delays of payment of hospitals, shipment to hospitals, rings freely deposited in hospitals are under the management of the distributor.
Sales in USA
Once the U.S. distribution channel is chosen, the sales strategy will be discussed together with the U.S. company. It does not differ fundamentally from Europe. The major difference is the the U.S. sales team may belong to the U.S. distributor, or be independent from the U.S. distributor.
Sales in Other Parts of the World
It is intended to act as in Europe: nominate a local distributor who is able to have easy access to the cardiac surgeons community of his country.
Our sales forecast assumes no change in costs or prices, which is a reasonable assumption for the last few years.We are expecting to increase sales from $2.5 million (4,000 rings) to $10 million (16,000 rings) the second year. The growth forecast is very high, but we are developing new products. We expect growth of the pediatric market, where the product is really needed. We are not projecting significant change in the product line, or in the proportion between different lines.
Sales Forecast | |||
Year 1 | Year 2 | Year 3 | |
Unit Sales | |||
K. Biodegradable Ring | 4,000 | 16,000 | 24,000 |
Other | 0 | 0 | 0 |
Total Unit Sales | 4,000 | 16,000 | 24,000 |
Unit Prices | Year 1 | Year 2 | Year 3 |
K. Biodegradable Ring | $625.00 | $625.00 | $625.00 |
Other | $0.00 | $0.00 | $0.00 |
Sales | |||
K. Biodegradable Ring | $2,500,000 | $10,000,000 | $15,000,000 |
Other | $0 | $0 | $0 |
Total Sales | $2,500,000 | $10,000,000 | $15,000,000 |
Direct Unit Costs | Year 1 | Year 2 | Year 3 |
K. Biodegradable Ring | $35.00 | $35.00 | $35.00 |
Other | $0.00 | $0.00 | $0.00 |
Direct Cost of Sales | |||
K. Biodegradable Ring | $140,000 | $560,000 | $840,000 |
Other | $0 | $0 | $0 |
Subtotal Direct Cost of Sales | $140,000 | $560,000 | $840,000 |
The company will mainly sell outside Switzerland, which is representing a very small market. It intends to develop persistent efforts to generate the distribution through major names in each country.
It intends to hire a marketing and sales executive, and a clinical director by 2002. Both positions will support international sales, by training the sales team, assisting them with key customers, and participating in international meetings.
We have been contacted by several major U.S. companies, (Medtronic, St Jude), who are interested with our product line. In case they would wish to distribute the products worldwide, we would have to negotiate a fair fee for international exclusive distribution (U.S. $2 million), as well as the different involvements of both parties concerning regulatory affairs, marketing, clinical studies.
We would need to understand the real interest of these companies: do they wish to buy Bioring on a middle-term plan? At what price? What do they intend to do with Bioring’s manufacturing facility? The board is of the opinion that a fair offer from one of these companies should be seriously studied.
The accompanying table shows specific milestones, with responsibilities assigned, dates, and budgets. We are focusing, in this plan, on a few key milestones that should be accomplished.
Milestones | |||||
Milestone | Start Date | End Date | Budget | Manager | Department |
Initial Swiss Patent Deposit | 7/1/1997 | 7/1/1997 | $0 | Andrieu | Management |
Setting up manufacturing facility | 5/1/2000 | 3/1/2001 | $450,000 | Andrieu/LeGoff | Managment |
PCT extension of the patent | 9/1/2000 | 11/1/2000 | $10,000 | Le Goff | R & D |
Hiring of production staff | 10/1/2000 | 10/1/2000 | $0 | Andrieu | Production |
Product technical development | 5/1/2000 | 3/1/2001 | $0 | Andrieu/Le Goff | R & D |
CE mark approval | 4/1/2001 | 6/1/2001 | $15,000 | Le Goff | R & D |
European distribution network | 5/1/2001 | 7/1/2001 | $0 | Andrieu | Management |
FDA approval process | 10/1/2001 | 12/1/2002 | $200,000 | Andrieu | Management |
USA distribution network | 6/1/2002 | 12/1/2002 | $0 | Andrieu | Management |
ROW distribution network | 9/1/2002 | 3/1/2003 | $200,000 | Andrieu | Management |
Totals | $875,000 |
Bioring SA is slow to hire new people, and very loyal to those who are hired.
Immediate personnel plans call for increases from five to seven people two years from now. The increase is needed to support the effort to move on a real international base.
Management style reflects the participation of the owners. The company respects its community of co-workers and treats all workers well. We attempt to develop and nurture the company as a community.
Raymond Andrieu, president, is responsible for overall business management.
Philippe Le Goff, consultant, is responsible for product development, quality insurance and CE mark approval. He closely collaborates with Raymond Andrieu.
Afksendiyos Kalengos, cardiac surgeon, is responsible for the final presentation of the product, its adequation to the clinical needs, and clinical studies. He closely collaborates with Raymond Andrieu and Philippe Le Goff.
Danielle Collomb, assistant to the president, is responsible for relations with furnisher, orders to furnisher and all administrative current workload.
Marlyse Bertholet and Marie-José Raposo are producing the products. They report directly to Raymond Andrieu.
The company is managed by:
Afksendiyos Kalengos: assistant pediatric and adult cardiac surgeon in Geneva University Hospital. He has also been nominated professor in foreign universities. He is presently following an MBA program during his free hours. He is considered as the reference surgeon in pediatric cardiac surgery in Switzerland. He developed the original idea together with the founder. He has a Ph.D., is 41 years old, a Swiss citizen, married and has two children.
Philippe Le Goff: chemical engineer, has a Ph.D. from Polytechnique School in Paris, where he ranked second and his wife as the “major” (first rank). He participated to the final development of the polymer synthesis. He is consultant to major pharmaceutical companies, where he is mainly in charge of the approval of the new synthesis pilot production for drugs by the regulatory authorities (CE and FDA). He is also in charge of developing industrial production based on pilot production and approval by authorities. He is a 38 years old French citizen, with Swiss residence approval, married with two children.
There are two gaps in the planning process:
The personnel plan has been projected to cover the production needs over the considered period.
Two production people, working eight hours a day, five days a week, are able to manufacture up to 25,000 rings a year. If we add another team of two people, the production capacity reaches 50,000 rings a year.
The personnel table assumes 5% per annum pay raises. We already have a strong benefits policy with fully paid medical insurance for employees. We therefore expect very low turnover. A stock option plan is under study by our auditing company for Mr. Philippe Le Goff.
Salaries are generally in line with market pay for Lausanne and Geneva area, although our benefits are above standard market level, so we ultimately pay a bit more for our people than what might be considered industrial standard in the area. However, we are at the same level in our industrial area that local medical companies and biotech companies.
Personnel Plan | |||
Year 1 | Year 2 | Year 3 | |
Production Personnel | |||
M. Bertholet | $7,605 | $36,000 | $38,500 |
M.J. Raposo | $7,125 | $34,200 | $36,000 |
Name or title | $0 | $0 | $0 |
Other | $0 | $0 | $0 |
Subtotal | $14,730 | $70,200 | $74,500 |
Sales and Marketing Personnel | |||
R. Andrieu 80% | $58,500 | $78,000 | $0 |
D. Collomb 20% | $6,750 | $0 | $0 |
Clinical Director | $0 | $0 | $60,000 |
Marketing Executive | $0 | $0 | $81,250 |
Other | $0 | $0 | $40,000 |
Subtotal | $65,250 | $78,000 | $181,250 |
General and Administrative Personnel | |||
R. Andrieu 20% | $0 | $0 | $102,000 |
D. Collomb 80% | $27,000 | $47,000 | $50,000 |
CE mark consulting fees | $0 | $15,500 | $2,000 |
FDA consulting fees | $0 | $0 | $200,000 |
Other | $2,115 | $3,000 | $5,000 |
Subtotal | $29,115 | $65,500 | $359,000 |
Other Personnel | |||
P.Le Goff | $0 | $90,000 | $100,000 |
Name or title | $0 | $0 | $0 |
Name or title | $0 | $0 | $0 |
Other | $0 | $0 | $0 |
Subtotal | $0 | $90,000 | $100,000 |
Total People | 0 | 0 | 0 |
Total Payroll | $109,095 | $303,700 | $714,750 |
The financial picture is quite encouraging. Sales are projected to start slowly, but this is due to the necessity of receiving CE mark. We need a second round of financing in April 2000 to start the sales on the market. The company has financed all machinery and tools and does not have any credit line. The original investors have been financing the development.
We want to finance growth mainly through cash flow. Collection days is very important. We do not want to let our average collection days get above 45 under any circumstances. We must maintain gross profit margins of 90% at the least, and hold marketing costs to no more than 5%. We are planning to receive tax exemption from the Canton of Vaud, which means that only federal tax is due to payment on net profit (around 10%) in FY2000. In the following years the total tax rate will be 25%
The financial plan depends on important assumptions, most of which are shown in the following table. The key underlying assumptions are:
General Assumptions | |||
Year 1 | Year 2 | Year 3 | |
Plan Month | 1 | 2 | 3 |
Current Interest Rate | 6.00% | 6.00% | 6.00% |
Long-term Interest Rate | 5.00% | 5.00% | 5.00% |
Tax Rate | 11.67% | 10.00% | 11.67% |
Other | 0 | 0 | 0 |
The following chart shows changes in key financial indicators: sales, gross margin, operating expenses, collection days, and inventory turnover.
Our Break-even Analysis is based on running costs, the “burn-rate” costs we incur to keep the business running, not on theoretical fixed costs that would be relevant only if we were closing. Between payroll, rent, utilities, and basic marketing costs, we think the number shown in the table is a good estimate of fixed costs.
The Break-even Analysis shows that Bioring has a good balance of fixed costs and sufficient sales strength to remain healthy. The essential insight here is that our sales level seems to be running comfortably above break-even.
Break-even Analysis | |
Monthly Units Break-even | 38 |
Monthly Revenue Break-even | $23,710 |
Assumptions: | |
Average Per-Unit Revenue | $625.00 |
Average Per-Unit Variable Cost | $35.00 |
Estimated Monthly Fixed Cost | $22,382 |
We expect sales to hit $2,500,000 for this year. It should increase to $10 million by the second year of this plan, as net earnings increase steadily. Our high sales volume has lowered our cost of goods and increased our gross margin. This increase in gross margin is important to profitability.
Pro Forma Profit and Loss | |||
Year 1 | Year 2 | Year 3 | |
Sales | $2,500,000 | $10,000,000 | $15,000,000 |
Direct Cost of Sales | $140,000 | $560,000 | $840,000 |
Production Payroll | $14,730 | $70,200 | $74,500 |
Other | $0 | $0 | $0 |
Total Cost of Sales | $154,730 | $630,200 | $914,500 |
Gross Margin | $2,345,270 | $9,369,800 | $14,085,500 |
Gross Margin % | 93.81% | 93.70% | 93.90% |
Operating Expenses | |||
Sales and Marketing Expenses | |||
Sales and Marketing Payroll | $65,250 | $78,000 | $181,250 |
Advertising/Promotion | $0 | $35,000 | $50,000 |
Travel | $6,000 | $24,000 | $35,000 |
Miscellaneous | $13,500 | $20,000 | $30,000 |
Total Sales and Marketing Expenses | $84,750 | $157,000 | $296,250 |
Sales and Marketing % | 3.39% | 1.57% | 1.98% |
General and Administrative Expenses | |||
General and Administrative Payroll | $29,115 | $65,500 | $359,000 |
Sales and Marketing and Other Expenses | $0 | $0 | $0 |
Depreciation | $72,000 | $96,000 | $96,000 |
Patent fees for PCT | $10,000 | $70,000 | $70,000 |
Utilities | $3,150 | $5,400 | $6,000 |
Insurance | $9,000 | $12,000 | $13,000 |
Rent | $33,300 | $444,400 | $45,000 |
Payroll Taxes | $27,274 | $75,925 | $178,688 |
Other General and Administrative Expenses | $0 | $0 | $0 |
Total General and Administrative Expenses | $183,839 | $769,225 | $767,688 |
General and Administrative % | 7.35% | 7.69% | 5.12% |
Other Expenses: | |||
Other Payroll | $0 | $90,000 | $100,000 |
Consultants | $0 | $0 | $0 |
Royalties Dr. A.Kalangos | $0 | $125,000 | $493,750 |
Total Other Expenses | $0 | $215,000 | $593,750 |
Other % | 0.00% | 2.15% | 3.96% |
Total Operating Expenses | $268,589 | $1,141,225 | $1,657,688 |
Profit Before Interest and Taxes | $2,076,681 | $8,228,575 | $12,427,813 |
EBITDA | $2,148,681 | $8,324,575 | $12,523,813 |
Interest Expense | $0 | $0 | $0 |
Taxes Incurred | $207,668 | $822,858 | $1,449,911 |
Net Profit | $1,869,013 | $7,405,718 | $10,977,901 |
Net Profit/Sales | 74.76% | 74.06% | 73.19% |
We expect to manage cash flow over the next three years with $100,000 of new investment in April 2000. This additional financing resources are required to finance the working capital.
Pro Forma Cash Flow | |||
Year 1 | Year 2 | Year 3 | |
Cash Received | |||
Cash from Operations | |||
Cash Sales | $625,000 | $2,500,000 | $3,750,000 |
Cash from Receivables | $1,414,063 | $6,117,188 | $10,328,125 |
Subtotal Cash from Operations | $2,039,063 | $8,617,188 | $14,078,125 |
Additional Cash Received | |||
Sales Tax, VAT, HST/GST Received | $0 | $0 | $0 |
New Current Borrowing | $0 | $0 | $0 |
New Other Liabilities (interest-free) | $0 | $0 | $0 |
New Long-term Liabilities | $0 | $0 | $0 |
Sales of Other Current Assets | $0 | $0 | $0 |
Sales of Long-term Assets | $0 | $0 | $0 |
New Investment Received | $100,000 | $0 | $0 |
Subtotal Cash Received | $2,139,063 | $8,617,188 | $14,078,125 |
Expenditures | Year 1 | Year 2 | Year 3 |
Expenditures from Operations | |||
Cash Spending | $109,095 | $303,700 | $714,750 |
Bill Payments | $333,104 | $2,128,248 | $3,167,861 |
Subtotal Spent on Operations | $442,199 | $2,431,948 | $3,882,611 |
Additional Cash Spent | |||
Sales Tax, VAT, HST/GST Paid Out | $0 | $0 | $0 |
Principal Repayment of Current Borrowing | $0 | $0 | $0 |
Other Liabilities Principal Repayment | $0 | $0 | $0 |
Long-term Liabilities Principal Repayment | $0 | $0 | $0 |
Purchase Other Current Assets | $0 | $0 | $0 |
Purchase Long-term Assets | $0 | $100,000 | $200,000 |
Dividends | $0 | $0 | $0 |
Subtotal Cash Spent | $442,199 | $2,531,948 | $4,082,611 |
Net Cash Flow | $1,696,864 | $6,085,240 | $9,995,514 |
Cash Balance | $1,725,864 | $7,811,104 | $17,806,618 |
As shown in the balance sheet in the following table, we expect a healthy growth in net worth. The monthly projections are in the appendix.
Pro Forma Balance Sheet | |||
Year 1 | Year 2 | Year 3 | |
Assets | |||
Current Assets | |||
Cash | $1,725,864 | $7,811,104 | $17,806,618 |
Accounts Receivable | $460,938 | $1,843,750 | $2,765,625 |
Inventory | $19,250 | $77,000 | $115,500 |
Other Current Assets | $0 | $0 | $0 |
Total Current Assets | $2,206,051 | $9,731,854 | $20,687,743 |
Long-term Assets | |||
Long-term Assets | $280,000 | $380,000 | $580,000 |
Accumulated Depreciation | $72,000 | $168,000 | $264,000 |
Total Long-term Assets | $208,000 | $212,000 | $316,000 |
Total Assets | $2,414,051 | $9,943,854 | $21,003,743 |
Liabilities and Capital | Year 1 | Year 2 | Year 3 |
Current Liabilities | |||
Accounts Payable | $61,038 | $185,123 | $267,111 |
Current Borrowing | $0 | $0 | $0 |
Other Current Liabilities | $0 | $0 | $0 |
Subtotal Current Liabilities | $61,038 | $185,123 | $267,111 |
Long-term Liabilities | $0 | $0 | $0 |
Total Liabilities | $61,038 | $185,123 | $267,111 |
Paid-in Capital | $742,500 | $742,500 | $742,500 |
Retained Earnings | ($258,500) | $1,610,513 | $9,016,231 |
Earnings | $1,869,013 | $7,405,718 | $10,977,901 |
Total Capital | $2,353,013 | $9,758,731 | $20,736,632 |
Total Liabilities and Capital | $2,414,051 | $9,943,854 | $21,003,743 |
Net Worth | $2,353,013 | $9,758,731 | $20,736,632 |
Our ratios look healthy and solid. Gross margin is projected to stay above 95%, and return on assets and return on equity are very sound. Debt and liquidity ratios also look very good, with debt to net worth running at respectively 0,34, 0,05 and 0,02. The projections, if we make them, are those of a very solid company. Industry profile ratios based on the Standard Industrial Classification (SIC) code 3842, Surgical Appliances and Supplies, are shown for comparison.
Ratio Analysis | ||||
Year 1 | Year 2 | Year 3 | Industry Profile | |
Sales Growth | 0.00% | 300.00% | 50.00% | 6.10% |
Percent of Total Assets | ||||
Accounts Receivable | 19.09% | 18.54% | 13.17% | 25.00% |
Inventory | 0.80% | 0.77% | 0.55% | 15.90% |
Other Current Assets | 0.00% | 0.00% | 0.00% | 38.00% |
Total Current Assets | 91.38% | 97.87% | 98.50% | 78.90% |
Long-term Assets | 8.62% | 2.13% | 1.50% | 21.10% |
Total Assets | 100.00% | 100.00% | 100.00% | 100.00% |
Current Liabilities | 2.53% | 1.86% | 1.27% | 37.60% |
Long-term Liabilities | 0.00% | 0.00% | 0.00% | 20.20% |
Total Liabilities | 2.53% | 1.86% | 1.27% | 57.80% |
Net Worth | 97.47% | 98.14% | 98.73% | 42.20% |
Percent of Sales | ||||
Sales | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin | 93.81% | 93.70% | 93.90% | 47.70% |
Selling, General & Administrative Expenses | 19.05% | 31.98% | 31.76% | 28.20% |
Advertising Expenses | 0.00% | 0.35% | 0.33% | 1.60% |
Profit Before Interest and Taxes | 83.07% | 82.29% | 82.85% | 4.90% |
Main Ratios | ||||
Current | 36.14 | 52.57 | 77.45 | 2.03 |
Quick | 35.83 | 52.15 | 77.02 | 1.35 |
Total Debt to Total Assets | 2.53% | 1.86% | 1.27% | 57.80% |
Pre-tax Return on Net Worth | 88.26% | 84.32% | 59.93% | 5.70% |
Pre-tax Return on Assets | 86.02% | 82.75% | 59.17% | 13.40% |
Additional Ratios | Year 1 | Year 2 | Year 3 | |
Net Profit Margin | 74.76% | 74.06% | 73.19% | n.a |
Return on Equity | 79.43% | 75.89% | 52.94% | n.a |
Activity Ratios | ||||
Accounts Receivable Turnover | 4.07 | 4.07 | 4.07 | n.a |
Collection Days | 56 | 56 | 75 | n.a |
Inventory Turnover | 3.15 | 11.64 | 8.73 | n.a |
Accounts Payable Turnover | 6.46 | 12.17 | 12.17 | n.a |
Payment Days | 27 | 20 | 25 | n.a |
Total Asset Turnover | 1.04 | 1.01 | 0.71 | n.a |
Debt Ratios | ||||
Debt to Net Worth | 0.03 | 0.02 | 0.01 | n.a |
Current Liab. to Liab. | 1.00 | 1.00 | 1.00 | n.a |
Liquidity Ratios | ||||
Net Working Capital | $2,145,013 | $9,546,731 | $20,420,632 | n.a |
Interest Coverage | 0.00 | 0.00 | 0.00 | n.a |
Additional Ratios | ||||
Assets to Sales | 0.97 | 0.99 | 1.40 | n.a |
Current Debt/Total Assets | 3% | 2% | 1% | n.a |
Acid Test | 28.28 | 42.19 | 66.66 | n.a |
Sales/Net Worth | 1.06 | 1.02 | 0.72 | n.a |
Dividend Payout | 0.00 | 0.00 | 0.00 | n.a |
Sales Forecast | |||||||||||||
Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | ||
Unit Sales | |||||||||||||
K. Biodegradable Ring | 0% | 0 | 0 | 0 | 0 | 0 | 1,000 | 500 | 500 | 500 | 500 | 500 | 500 |
Other | 0% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Unit Sales | 0 | 0 | 0 | 0 | 0 | 1,000 | 500 | 500 | 500 | 500 | 500 | 500 | |
Unit Prices | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
K. Biodegradable Ring | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $625.00 | $625.00 | $625.00 | $625.00 | $625.00 | $625.00 | $625.00 | |
Other | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
Sales | |||||||||||||
K. Biodegradable Ring | $0 | $0 | $0 | $0 | $0 | $625,000 | $312,500 | $312,500 | $312,500 | $312,500 | $312,500 | $312,500 | |
Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Total Sales | $0 | $0 | $0 | $0 | $0 | $625,000 | $312,500 | $312,500 | $312,500 | $312,500 | $312,500 | $312,500 | |
Direct Unit Costs | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
K. Biodegradable Ring | 0.00% | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $35.00 | $35.00 | $35.00 | $35.00 | $35.00 | $35.00 | $35.00 |
Other | 0.00% | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Direct Cost of Sales | |||||||||||||
K. Biodegradable Ring | $0 | $0 | $0 | $0 | $0 | $35,000 | $17,500 | $17,500 | $17,500 | $17,500 | $17,500 | $17,500 | |
Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Subtotal Direct Cost of Sales | $0 | $0 | $0 | $0 | $0 | $35,000 | $17,500 | $17,500 | $17,500 | $17,500 | $17,500 | $17,500 |
Personnel Plan | |||||||||||||
Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | ||
Production Personnel | |||||||||||||
M. Bertholet | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1,505 | $3,050 | $3,050 | |
M.J. Raposo | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1,425 | $2,850 | $2,850 | |
Name or title | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Subtotal | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2,930 | $5,900 | $5,900 | |
Sales and Marketing Personnel | |||||||||||||
R. Andrieu 80% | $0 | $0 | $0 | $6,500 | $6,500 | $6,500 | $6,500 | $6,500 | $6,500 | $6,500 | $6,500 | $6,500 | |
D. Collomb 20% | $0 | $0 | $0 | $750 | $750 | $750 | $750 | $750 | $750 | $750 | $750 | $750 | |
Clinical Director | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Marketing Executive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Subtotal | $0 | $0 | $0 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | |
General and Administrative Personnel | |||||||||||||
R. Andrieu 20% | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
D. Collomb 80% | $0 | $0 | $0 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | |
CE mark consulting fees | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
FDA consulting fees | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Other | $0 | $0 | $0 | $235 | $235 | $235 | $235 | $235 | $235 | $235 | $235 | $235 | |
Subtotal | $0 | $0 | $0 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | |
Other Personnel | |||||||||||||
P.Le Goff | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Name or title | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Name or title | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Subtotal | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Total People | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total Payroll | $0 | $0 | $0 | $10,485 | $10,485 | $10,485 | $10,485 | $10,485 | $10,485 | $13,415 | $16,385 | $16,385 |
General Assumptions | |||||||||||||
Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | ||
Plan Month | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
Current Interest Rate | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | 6.00% | |
Long-term Interest Rate | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | 5.00% | |
Tax Rate | 30.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | |
Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pro Forma Profit and Loss | |||||||||||||
Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | ||
Sales | $0 | $0 | $0 | $0 | $0 | $625,000 | $312,500 | $312,500 | $312,500 | $312,500 | $312,500 | $312,500 | |
Direct Cost of Sales | $0 | $0 | $0 | $0 | $0 | $35,000 | $17,500 | $17,500 | $17,500 | $17,500 | $17,500 | $17,500 | |
Production Payroll | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2,930 | $5,900 | $5,900 | |
Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Total Cost of Sales | $0 | $0 | $0 | $0 | $0 | $35,000 | $17,500 | $17,500 | $17,500 | $20,430 | $23,400 | $23,400 | |
Gross Margin | $0 | $0 | $0 | $0 | $0 | $590,000 | $295,000 | $295,000 | $295,000 | $292,070 | $289,100 | $289,100 | |
Gross Margin % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 94.40% | 94.40% | 94.40% | 94.40% | 93.46% | 92.51% | 92.51% | |
Operating Expenses | |||||||||||||
Sales and Marketing Expenses | |||||||||||||
Sales and Marketing Payroll | $0 | $0 | $0 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | $7,250 | |
Advertising/Promotion | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Travel | $0 | $0 | $0 | $0 | $0 | $2,000 | $0 | $0 | $2,000 | $0 | $2,000 | $0 | |
Miscellaneous | $0 | $0 | $0 | $1,500 | $1,500 | $1,500 | $1,500 | $1,500 | $1,500 | $1,500 | $1,500 | $1,500 | |
Total Sales and Marketing Expenses | $0 | $0 | $0 | $8,750 | $8,750 | $10,750 | $8,750 | $8,750 | $10,750 | $8,750 | $10,750 | $8,750 | |
Sales and Marketing % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.72% | 2.80% | 2.80% | 3.44% | 2.80% | 3.44% | 2.80% | |
General and Administrative Expenses | |||||||||||||
General and Administrative Payroll | $0 | $0 | $0 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | $3,235 | |
Sales and Marketing and Other Expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Depreciation | $0 | $0 | $0 | $8,000 | $8,000 | $8,000 | $8,000 | $8,000 | $8,000 | $8,000 | $8,000 | $8,000 | |
Patent fees for PCT | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $10,000 | |
Utilities | $0 | $0 | $0 | $350 | $350 | $350 | $350 | $350 | $350 | $350 | $350 | $350 | |
Insurance | $0 | $0 | $0 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | |
Rent | $0 | $0 | $0 | $3,700 | $3,700 | $3,700 | $3,700 | $3,700 | $3,700 | $3,700 | $3,700 | $3,700 | |
Payroll Taxes | 25% | $0 | $0 | $0 | $2,621 | $2,621 | $2,621 | $2,621 | $2,621 | $2,621 | $3,354 | $4,096 | $4,096 |
Other General and Administrative Expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Total General and Administrative Expenses | $0 | $0 | $0 | $18,906 | $18,906 | $18,906 | $18,906 | $18,906 | $18,906 | $19,639 | $20,381 | $30,381 | |
General and Administrative % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.03% | 6.05% | 6.05% | 6.05% | 6.28% | 6.52% | 9.72% | |
Other Expenses: | |||||||||||||
Other Payroll | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Consultants | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Royalties Dr. A.Kalangos | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Total Other Expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Other % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
Total Operating Expenses | $0 | $0 | $0 | $27,656 | $27,656 | $29,656 | $27,656 | $27,656 | $29,656 | $28,389 | $31,131 | $39,131 | |
Profit Before Interest and Taxes | $0 | $0 | $0 | ($27,656) | ($27,656) | $560,344 | $267,344 | $267,344 | $265,344 | $263,681 | $257,969 | $249,969 | |
EBITDA | $0 | $0 | $0 | ($19,656) | ($19,656) | $568,344 | $275,344 | $275,344 | $273,344 | $271,681 | $265,969 | $257,969 | |
Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Taxes Incurred | $0 | $0 | $0 | ($2,766) | ($2,766) | $56,034 | $26,734 | $26,734 | $26,534 | $26,368 | $25,797 | $24,997 | |
Net Profit | $0 | $0 | $0 | ($24,891) | ($24,891) | $504,309 | $240,609 | $240,609 | $238,809 | $237,313 | $232,172 | $224,972 | |
Net Profit/Sales | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 80.69% | 77.00% | 77.00% | 76.42% | 75.94% | 74.30% | 71.99% |
Pro Forma Cash Flow | |||||||||||||
Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | ||
Cash Received | |||||||||||||
Cash from Operations | |||||||||||||
Cash Sales | $0 | $0 | $0 | $0 | $0 | $156,250 | $78,125 | $78,125 | $78,125 | $78,125 | $78,125 | $78,125 | |
Cash from Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $15,625 | $460,938 | $234,375 | $234,375 | $234,375 | $234,375 | |
Subtotal Cash from Operations | $0 | $0 | $0 | $0 | $0 | $156,250 | $93,750 | $539,063 | $312,500 | $312,500 | $312,500 | $312,500 | |
Additional Cash Received | |||||||||||||
Sales Tax, VAT, HST/GST Received | 0.00% | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
New Current Borrowing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
New Other Liabilities (interest-free) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
New Long-term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Sales of Other Current Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Sales of Long-term Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
New Investment Received | $0 | $0 | $0 | $100,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Subtotal Cash Received | $0 | $0 | $0 | $100,000 | $0 | $156,250 | $93,750 | $539,063 | $312,500 | $312,500 | $312,500 | $312,500 | |
Expenditures | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
Expenditures from Operations | |||||||||||||
Cash Spending | $0 | $0 | $0 | $10,485 | $10,485 | $10,485 | $10,485 | $10,485 | $10,485 | $13,415 | $16,385 | $16,385 | |
Bill Payments | $0 | $0 | $0 | $214 | $6,406 | $8,432 | $66,162 | $36,381 | $50,324 | $55,158 | $53,844 | $56,183 | |
Subtotal Spent on Operations | $0 | $0 | $0 | $10,699 | $16,891 | $18,917 | $76,647 | $46,866 | $60,809 | $68,573 | $70,229 | $72,568 | |
Additional Cash Spent | |||||||||||||
Sales Tax, VAT, HST/GST Paid Out | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Principal Repayment of Current Borrowing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Other Liabilities Principal Repayment | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Long-term Liabilities Principal Repayment | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Purchase Other Current Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Purchase Long-term Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Dividends | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
Subtotal Cash Spent | $0 | $0 | $0 | $10,699 | $16,891 | $18,917 | $76,647 | $46,866 | $60,809 | $68,573 | $70,229 | $72,568 | |
Net Cash Flow | $0 | $0 | $0 | $89,301 | ($16,891) | $137,333 | $17,103 | $492,197 | $251,691 | $243,927 | $242,271 | $239,932 | |
Cash Balance | $29,000 | $29,000 | $29,000 | $118,301 | $101,411 | $238,744 | $255,846 | $748,043 | $999,734 | $1,243,661 | $1,485,932 | $1,725,864 |
Pro Forma Balance Sheet | |||||||||||||
Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | ||
Assets | Starting Balances | ||||||||||||
Current Assets | |||||||||||||
Cash | $29,000 | $29,000 | $29,000 | $29,000 | $118,301 | $101,411 | $238,744 | $255,846 | $748,043 | $999,734 | $1,243,661 | $1,485,932 | $1,725,864 |
Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $468,750 | $687,500 | $460,938 | $460,938 | $460,938 | $460,938 | $460,938 |
Inventory | $75,000 | $75,000 | $75,000 | $75,000 | $75,000 | $75,000 | $40,000 | $22,500 | $19,250 | $19,250 | $19,250 | $19,250 | $19,250 |
Other Current Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Total Current Assets | $104,000 | $104,000 | $104,000 | $104,000 | $193,301 | $176,411 | $747,494 | $965,846 | $1,228,231 | $1,479,922 | $1,723,849 | $1,966,120 | $2,206,051 |
Long-term Assets | |||||||||||||
Long-term Assets | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 | $280,000 |
Accumulated Depreciation | $0 | $0 | $0 | $0 | $8,000 | $16,000 | $24,000 | $32,000 | $40,000 | $48,000 | $56,000 | $64,000 | $72,000 |
Total Long-term Assets | $280,000 | $280,000 | $280,000 | $280,000 | $272,000 | $264,000 | $256,000 | $248,000 | $240,000 | $232,000 | $224,000 | $216,000 | $208,000 |
Total Assets | $384,000 | $384,000 | $384,000 | $384,000 | $465,301 | $440,411 | $1,003,494 | $1,213,846 | $1,468,231 | $1,711,922 | $1,947,849 | $2,182,120 | $2,414,051 |
Liabilities and Capital | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
Current Liabilities | |||||||||||||
Accounts Payable | $0 | $0 | $0 | $0 | $6,192 | $6,192 | $64,965 | $34,709 | $48,484 | $53,365 | $51,979 | $54,078 | $61,038 |
Current Borrowing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Other Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Subtotal Current Liabilities | $0 | $0 | $0 | $0 | $6,192 | $6,192 | $64,965 | $34,709 | $48,484 | $53,365 | $51,979 | $54,078 | $61,038 |
Long-term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Total Liabilities | $0 | $0 | $0 | $0 | $6,192 | $6,192 | $64,965 | $34,709 | $48,484 | $53,365 | $51,979 | $54,078 | $61,038 |
Paid-in Capital | $642,500 | $642,500 | $642,500 | $642,500 | $742,500 | $742,500 | $742,500 | $742,500 | $742,500 | $742,500 | $742,500 | $742,500 | $742,500 |
Retained Earnings | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) | ($258,500) |
Earnings | $0 | $0 | $0 | $0 | ($24,891) | ($49,781) | $454,528 | $695,138 | $935,747 | $1,174,556 | $1,411,869 | $1,644,041 | $1,869,013 |
Total Capital | $384,000 | $384,000 | $384,000 | $384,000 | $459,109 | $434,219 | $938,528 | $1,179,138 | $1,419,747 | $1,658,556 | $1,895,869 | $2,128,041 | $2,353,013 |
Total Liabilities and Capital | $384,000 | $384,000 | $384,000 | $384,000 | $465,301 | $440,411 | $1,003,494 | $1,213,846 | $1,468,231 | $1,711,922 | $1,947,849 | $2,182,120 | $2,414,051 |
Net Worth | $384,000 | $384,000 | $384,000 | $384,000 | $459,109 | $434,219 | $938,528 | $1,179,138 | $1,419,747 | $1,658,556 | $1,895,869 | $2,128,041 | $2,353,013 |
Fill-in-the-blanks and automatic financials make it easy.
No thanks, I prefer writing 40-page documents.
Discover the world’s #1 plan building software
Advertisement
Supported by
The vice president supports the tax increases proposed by the Biden White House, according to her campaign.
By Andrew Duehren
Reporting from Washington
In a campaign otherwise light on policy specifics, Vice President Kamala Harris this week quietly rolled out her most detailed, far-ranging proposal yet: nearly $5 trillion in tax increases over a decade.
That’s how much more revenue the federal government would raise if it adopted a number of tax increases that President Biden proposed in the spring . Ms. Harris’s campaign said this week that she supported those tax hikes, which were thoroughly laid out in the most recent federal budget plan prepared by the Biden administration.
No one making less than $400,000 a year would see their taxes go up under the plan. Instead, Ms. Harris is seeking to significantly raise taxes on the wealthiest Americans and large corporations. Congress has previously rejected many of these tax ideas, even when Democrats controlled both chambers.
While tax policy is right now a subplot in a turbulent presidential campaign, it will be a primary policy issue in Washington next year. The next president will have to work with Congress to address the tax cuts Donald J. Trump signed into law in 2017. Many of those tax cuts expire after 2025, meaning millions of Americans will see their taxes go up if lawmakers don’t reach a deal next year.
Here’s an overview of what we now know — and still don’t know — about the Democratic nominee’s views on taxes.
The most recent White House budget includes several proposals that would raise taxes on large corporations . Chief among them is raising the corporate tax rate to 28 percent from 21 percent, a step that the Treasury Department estimated could bring in $1.3 trillion in revenue over the next 10 years.
We are having trouble retrieving the article content.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.
Thank you for your patience while we verify access.
Already a subscriber? Log in .
Want all of The Times? Subscribe .
Affiliate links for the products on this page are from partners that compensate us (see our advertiser disclosure with our list of partners for more details). However, our opinions are our own. See how we rate travel insurance products to write unbiased product reviews.
A few weeks ago, I started researching trips for my family and me over the winter holiday season. After pricing out flights, hotels, and rental cars for vacations in Europe or tropical islands, I decided to pivot my planning.
While it's been 15 years since my last cruise, I was able to find deals that were affordable for a family of three. But I wanted to make sure that if we booked the cruise now, we'd have proper coverage in case something stood in our way from going in December.
With a kid and two adults, you never know who will be sick in the winter months or what types of winter storms will roll through, which makes travel insurance essential.
While some travel insurance policies cover cruises, not all do. I decided to look into getting cruise travel insurance . Here's what it covers and how much it would cost for a family of three.
While cruise insurance policies offer a lot of the same coverage as travel insurance policies, they also offer additional add-on benefits that are relevant to cruises. I used a cruise travel insurance comparison site to find a plan through WorldTrips that covers all three of us for $386.
As I searched through quotes from different cruise travel insurance companies, I was able to select add-on coverage that I felt we needed. A lot of these options aren't usually offered with standard travel insurance.
For example, I added a hurricane and weather benefit. We live in New York City, and the cruise is in December. In case we're hit with a snowstorm or inclement weather, this policy allows us to cancel the cruise and receive a reimbursement. Without this coverage, we could miss the cruise and lose thousands of dollars.
One offering that cruise travel insurance companies usually have is a cancel for any reason upgrade. If we decide in the winter months not to go on the cruise anymore for no specific reason, we're able to get 75% of the cost of our trip back.
This perk is usually an add-on for cruise travel insurance policies, but it is worth it. Even though it doesn't give you a full refund, it allows you to recoup most of your cruise costs if you no longer want to go.
The typical trip cancellation benefit offered by travel insurance companies only provides reimbursement if the trip is canceled due to specific things like illness, injury, or death.
One of the biggest reasons I wanted cruise travel insurance for my family was to cover any and all medical costs that could happen while we're out at sea. In addition to standard coverage, like emergency medical coverage (the plan I picked offers $100,000 per person in coverage), the plan also covers medical evacuation and repatriation, up to $250,000 per person.
This is important to me because if one of us gets very ill and has to be transported to a medical facility or return back home, this benefit covers the costs of that.
To continue, please click the box below to let us know you're not a robot.
Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy .
For inquiries related to this message please contact our support team and provide the reference ID below.
IMAGES
VIDEO
COMMENTS
Step 8: Apply for Licenses and Permits. Starting a medical supply business requires obtaining a number of licenses and permits from local, state, and federal governments. Some states require a special license to sell certain types of medical supplies. Check with your state for requirements.
Medicare reimbursement for standard systems is set at $264.04 per year, with 80% covered by Medicare part B and the remaining 20% being a co-pay that is the responsibility of the resident. Our compensation plan will be a straight 16% commission paid when we receive reimbursement for delivered product.
If you are planning to start a new manufacturing business, the first thing you will need is a business plan. Use our Lanzor - medical equipment manufacturing business plan example created using Upmetrics business plan software to start writing your business plan in no time.. Before you start writing your business plan for your new medical equipment manufacturing business, spend as much time ...
The cost for start-up inventory (stocking with a wide range of medical and surgical equipment, instruments and supplies from different manufacturing brands) - $550,000. The cost for the purchase of distribution trucks - $29,500. The cost for store equipment (cash register, security, ventilation, signage) - $13,750.
MedNexis, Inc. (the company) is a medical device development company that has designed and patented medical devices which it plans to produce and market. A magnetic muscle stimulator/field generator has been designed with the participation of leading medical personnel and biomedical engineers. One patent is initially incorporated.
Voice Recognition Software Business Plan. Voice Control, Inc. was created to provide a solution to orthopedic surgeons. Specifically, the solution deals with the input of patient data into a medical records database. There will always be a need for medical equipment, so starting a business supplying it can be a great idea. An even better idea ...
MediTech LLC is currently seeking $1,400,000 to launch. The funding will be dedicated to the facility build out, purchase of initial equipment, working capital, marketing costs, and startup overhead expenses. The breakout of the funding is below: Facility design/build: $500,000. Equipment: $200,000.
How to write a medical supply business plan in 6 steps. In the sections below, we'll guide you through six essential steps to help you craft a comprehensive medical supply business plan that sets the stage for a thriving venture in the healthcare industry. Executive summary. Business and domain names.
Traditionally, a marketing plan includes the four P's: Product, Price, Place, and Promotion. For a medical device business plan, your marketing strategy should include the following: Product: In the product section, you should reiterate the type of medical device company that you documented in your company overview.
How to Write a Medical Supplies Business Plan in 7 Steps: 1. Describe the Purpose of Your Medical Supplies Business. The first step to writing your business plan is to describe the purpose of your medical supplies business. This includes describing why you are starting this type of business, and what problems it will solve for customers.
Additionally, a business plan for medical equipment or supplies will help you obtain funding from prospective investors. An effective business plan should incorporate a market analysis, financial projections, and a marketing strategy. It should also include a cost analysis of your products and services, and an assessment of potential risks to ...
1. Choose the Name for Your Medical Supply Business. The first step to starting a medical supply business is to choose your business' name. This is a very important choice since your company name is your brand and will last for the lifetime of your business. Ideally you choose a name that is meaningful and memorable.
When creating a business plan for a home medical equipment business, consider factors such as the cost of purchasing the medical supplies, warehouse or storage costs, marketing expenses, and potential revenue. Additionally, your business plan should include a strategy for navigating the regulatory and compliance aspects of the industry.
Medical equipment is any equipment that makes life easier for patients with ailments and diseases. Example of medical equipment include nebulizers, oxygen tents, wheelchairs, hospital beds, and iron lungs. If you are starting a medical equipment business plan, the following are a few questions to consider:
Shannon McKenzie© Medical Supply Company, Inc. is an American-based and licensed medical supply business that will be located in a well-furnished and centrally located warehouse facility in the heart of Fort Wayne, Indiana. At Shannon McKenzie© Medical Supply Company, Inc., we will supply a wide array of medical and surgical equipment ...
Sample Medical Equipment Business Plan - Free download as PDF File (.pdf), Text File (.txt) or read online for free. sample business plan for medical equipment sales
medical_equipment_-_supplies_business_plan - Free download as Word Doc (.doc / .docx), PDF File (.pdf), Text File (.txt) or read online for free.
Get the most out of your business plan example. Follow these tips to quickly develop a working business plan from this sample. 1. Don't worry about finding an exact match. We have over 550 sample business plan templates. So, make sure the plan is a close match, but don't get hung up on the details. Your business is unique and will differ from ...
Scribd is the world's largest social reading and publishing site.
Business plans are meant to be flexible, living documents that are revisited periodically as the business grows. Writing a manufacturing business plan is a good exercise in understanding what equipment will be needed, evaluating the size of the market your business is based in, and assessing your competition.
Medical equipment & suppliers. Find nursing homes including rehab services near me. Find and compare Medicare-certified nursing homes based on a location, and compare the quality of care they provide and their staffing. A nursing home is a place for people who can't be cared for at home and need 24-hour nursing care.
Vice President Kamala Harris is calling for the forgiveness of medical debt for millions of Americans. Around 1 in 5 U.S. households reported carry the debt.
Shares of beleaguered exercise equipment company Peloton rallied sharply on Thursday after it reported its first rise in sales in more than two years. The home fitness company brought in $644 ...
Securing a loan is a critical step for many small businesses looking to start, grow, or sustain their operations. Whether the funds are needed for purchasing equipment, expanding facilities, or managing cash flow, obtaining a loan can provide the necessary capital to help a business thrive. The importance of business loans cannot be overstated. However, the process of securing a loan can be ...
By bridging the financial gap, it ensures that one can get the best medical treatment..Business. treatment. health. Hero FinCorp Medical Loan. ... to tackle a medical emergency. These include hospitalisation, medicines, doctor's fees, surgery, diagnosis, therapy, medical equipment, and other related expenses. ... Look for a loan plan with ...
2.2 Start-up Summary. Our start-up expenses come to $258,500, which are mostly equipment, legal costs, patent costs and expenses associated with opening our first office and manufacturing facilities. Another $384,000 is required in start-up assets. The start-up costs are to be financed by direct owners' investment.
The tax plan would also try to tax the wealthiest Americans' investment gains before they sell the assets or die. People with more than $100 million in wealth would have to pay at least 25 ...
In addition to standard coverage, like emergency medical coverage (the plan I picked offers $100,000 per person in coverage), the plan also covers medical evacuation and repatriation, up to ...
The Boston Business Journal features local business news about Boston. We also provide tools to help businesses grow, network and hire.
Public health officials fighting a lethal outbreak of mpox in Africa are struggling to avoid mistakes that cost lives during the Covid-19 pandemic, starting with the slow acquisition of vaccines.